Barely Significant
← all excerpts

Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives.

Ther Adv Med Oncol · 2021 · PMC8264726 · PMID 34285720

Europe PMCDOI
1
hedged sentence
0.7130
closest p · 14.3× alpha
0.7130
boldest claim

The sentences

did not reach statistical significancep = 0.713not close (p > 0.1)
However, this did not reach statistical significance (mOS 10.3 versus 8.2 months, p = 0.713; mPFS 4.0 versus 3.3 months, p = 0.494). 45 A liposomal formulation of irinotecan (nal-IRI) was tested as a second-line therapy after a gemcitabine-based first-line in the phase III NAPOLI-1 trial. 14 , 46 A total of four hundred and seventeen patients were randomized into three groups: nal-IRI monotherapy, nal-IRI plus LV5FU2, or LV5FU2 monotherapy.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.